DAFTAR PUSTAKA

American Hearth Association. (2014). *Adult Basic Life Support : 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitationand Emergency Cardiovascular Care*. Circulation 2010.

Barrese, V., & Taglialatela, M. (2013). New advances in beta-blocker therapy in heart failure. *Frontiers in Physiology*, *4*. https://doi.org/10.3389/fphys.2013.00323

Bavishi, C., Chatterjee, S., Ather, S., Patel, D., & Messerli, F. H. (2015). Beta-blockers in heart failure with preserved ejection fraction: A meta-analysis. *Heart Failure Reviews*, *20*(2), 193–201. https://doi.org/10.1007/s10741-014-9453-8

Briasoulis, A., Palla, M., & Afonso, L. (2015). Meta-Analysis of the Effects of Carvedilol Versus Metoprolol on All-Cause Mortality and Hospitalizations in Patients With Heart Failure. *The American Journal of Cardiology*, *115*(8), 1111–1115. https://doi.org/10.1016/j.amjcard.2015.01.545

Burnett, H., Earley, A., Voors, A. A., Senni, M., McMurray, J. J. V., Deschaseaux, C., & Cope, S. (2017). Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis. *Circulation: Heart Failure*, *10*(1). https://doi.org/10.1161/CIRCHEARTFAILURE.116.003529

Casu, G., San Francesco Nuoro Hospital, Nuoro, Italy, Merella, P., & San Francesco Nuoro Hospital, Nuoro, Italy. (2015). Diuretic Therapy in Heart Failure – Current Approaches. *European Cardiology Review*, *10*(1), 42. https://doi.org/10.15420/ecr.2015.10.01.42

Chatterjee, S., Biondi-Zoccai, G., Abbate, A., D'Ascenzo, F., Castagno, D., Van Tassell, B., Mukherjee, D., & Lichstein, E. (2013). Benefits of blockers in patients with heart failure and reduced ejection fraction: Network meta-analysis. *BMJ*, *346*(jan16 1), f55–f55. https://doi.org/10.1136/bmj.f55

Cleland, J. G. F., Bunting, K. V., Flather, M. D., Altman, D. G., Holmes, J., Coats, A. J. S., Manzano, L., McMurray, J. J. V., Ruschitzka, F., van Veldhuisen, D. J., von

Lueder, T. G., Böhm, M., Andersson, B., Kjekshus, J., Packer, M., Rigby, A. S., Rosano, G., Wedel, H., Hjalmarson, Å., … Beta-blockers in Heart Failure Collaborative Group. (2018). Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: An individual patient-level analysis of double-blind randomized trials. *European Heart Journal*, *39*(1), 26–35. https://doi.org/10.1093/eurheartj/ehx564

Dahl Aarvik, M., Sandven, I., Dondo, T. B., Gale, C. P., Ruddox, V., Munkhaugen, J., Atar, D., & Otterstad, J. E. (2019). Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: A systematic review and meta-analysis. *European Heart Journal - Cardiovascular Pharmacotherapy*, *5*(1), 12–20. https://doi.org/10.1093/ehjcvp/pvy034

DiNicolantonio, J. J., Lavie, C. J., Fares, H., Menezes, A. R., & O'Keefe, J. H. (2013). Meta-Analysis of Carvedilol Versus Beta 1 Selective Beta-Blockers (Atenolol, Bisoprolol, Metoprolol, and Nebivolol). *The American Journal of Cardiology*, *111*(5), 765–769. https://doi.org/10.1016/j.amjcard.2012.11.031

Düngen, H.-D., Apostolović, S., Inkrot, S., Tahirović, E., Töpper, A., Mehrhof, F., Prettin, C., Putniković, B., Nešković, A. N., Krotin, M., Sakač, D., Lainščak, M., Edelmann, F., Wachter, R., Rau, T., Eschenhagen, T., Doehner, W., Anker, S. D., Waagstein, F., … on behalf of the CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure. (2011). Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: The CIBIS-ELD trial. *European Journal of Heart Failure*, *13*(6), 670–680. https://doi.org/10.1093/eurjhf/hfr020

Etminan, M., Jafari, S., Carleton, B., & FitzGerald, J. M. (2012). Beta-blocker use and COPD mortality: A systematic review and meta-analysis. *BMC Pulmonary Medicine*, *12*(1), 48. https://doi.org/10.1186/1471-2466-12-48

Ford, I., Robertson, M., Komajda, M., Böhm, M., Borer, J. S., Tavazzi, L., & Swedberg, K. (2015). Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model.

International Journal of Cardiology, *184*, 163–169. https://doi.org/10.1016/j.ijcard.2015.02.001

Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., … Yancy, C. W. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*, *145*(18). https://doi.org/10.1161/CIR.0000000000001063

Hori, M., Nagai, R., Izumi, T., & Matsuzaki, M. (2014). Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: Results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study. *Heart and Vessels*, *29*(2), 238–247. https://doi.org/10.1007/s00380-013-0340-3

Huang, B.-T., Huang, F.-Y., Zuo, Z.-L., Liao, Y.-B., Heng, Y., Wang, P.-J., Gui, Y.-Y., Xia, T.-L., Xin, Z.-M., Liu, W., Zhang, C., Chen, S.-J., Pu, X.-B., Chen, M., & Huang, D.-J. (2015). Meta-Analysis of Relation Between Oral β-Blocker Therapy and Outcomes in Patients With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. *The American Journal of Cardiology*, *115*(11), 1529–1538. https://doi.org/10.1016/j.amjcard.2015.02.057

Kemp, C. D., & Conte, J. V. (2012). The pathophysiology of heart failure. *Cardiovascular Pathology*, *21*(5), 365–371. https://doi.org/10.1016/j.carpath.2011.11.007

Koda-Kimble, M. A., & Alldredge, B. K. (Eds.). (2013). *Applied therapeutics: The clinical use of drugs* (10th ed). Wolters Kluwer/Lippincott Williams & Wilkins.

Konishi, M., Haraguchi, G., Kimura, S., Inagaki, H., Kawabata, M., Hachiya, H., Hirao, K., & Isobe, M. (2010). Comparative Effects of Carvedilol vs Bisoprolol for

Severe Congestive Heart Failure. *Circulation Journal*, *74*(6), 1127–1134. https://doi.org/10.1253/circj.CJ-09-0989

Kotecha, D., Chudasama, R., Lane, D. A., Kirchhof, P., & Lip, G. Y. H. (2016). Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. *International Journal of Cardiology*, *203*, 660–666. https://doi.org/10.1016/j.ijcard.2015.10.220

Kotecha, D., Flather, M. D., Altman, D. G., Holmes, J., Rosano, G., Wikstrand, J., Packer, M., Coats, A. J. S., Manzano, L., Böhm, M., van Veldhuisen, D. J., Andersson, B., Wedel, H., von Lueder, T. G., Rigby, A. S., Hjalmarson, Å., Kjekshus, J., & Cleland, J. G. F. (2017). Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. *Journal of the American College of Cardiology*, *69*(24), 2885–2896. https://doi.org/10.1016/j.jacc.2017.04.001

Kotecha, D., Holmes, J., Krum, H., Altman, D. G., Manzano, L., Cleland, J. G. F., Lip, G. Y. H., Coats, A. J. S., Andersson, B., Kirchhof, P., von Lueder, T. G., Wedel, H., Rosano, G., Shibata, M. C., Rigby, A., & Flather, M. D. (2014). Efficacy of β blockers in patients with heart failure plus atrial fibrillation: An individual-patient data meta-analysis. *The Lancet*, *384*(9961), 2235–2243. https://doi.org/10.1016/S0140-6736(14)61373-8

Krum, H., van Veldhuisen, D. J., Funck-Brentano, C., Vanoli, E., Silke, B., Erdmann, E., Follath, F., Ponikowski, P., Goulder, M., Meyer, W., Lechat, P., Willenheimer, R., & behalf of the CIBIS III Investigators. (2011). Effect on Mode of Death of Heart Failure Treatment Started with Bisoprolol Followed by Enalapril, Compared to the Opposite Order: Results of the Randomized CIBIS III Trial: Mode of Death in CIBIS III. *Cardiovascular Therapeutics*, *29*(2), 89–98. https://doi.org/10.1111/j.1755-5922.2010.00185.x

Ladage, D., Schwinger, R. H. G., & Brixius, K. (2013). Cardio-Selective Beta-Blocker: Pharmacological Evidence and Their Influence on Exercise Capacity: Cardio-

Selective Beta-Blocker. *Cardiovascular Therapeutics*, *31*(2), 76–83. https://doi.org/10.1111/j.1755-5922.2011.00306.x

Lin, T.-Y., Chen, C.-Y., & Huang, Y.-B. (2017). Evaluating the effectiveness of different beta-adrenoceptor blockers in heart failure patients. *International Journal of Cardiology*, *230*, 378–383. https://doi.org/10.1016/j.ijcard.2016.12.098

Lund, L. H., Benson, L., Dahlström, U., Edner, M., & Friberg, L. (2014). Association Between Use of β-Blockers and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. *JAMA*, *312*(19), 2008. https://doi.org/10.1001/jama.2014.15241

Masarone, D., Martucci, M. L., Errigo, V., & Pacileo, G. (2021). The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction. *Journal of Cardiovascular Development and Disease*, *8*(9), 101. https://doi.org/10.3390/jcdd8090101

Mulder, B. A., Damman, K., Van Veldhuisen, D. J., Van Gelder, I. C., & Rienstra, M. (2017). Heart rate and outcome in heart failure with reduced ejection fraction: Differences between atrial fibrillation and sinus rhythm—A CIBIS II analysis. *Clinical Cardiology*, *40*(9), 740–745. https://doi.org/10.1002/clc.22725

Mulder, B. A., van Veldhuisen, D. J., Crijns, H. J. G. M., Böhm, M., Cohen-Solal, A., Babalis, D., Roughton, M., Flather, M. D., Coats, A. J. S., & Van Gelder, I. C. (2012). Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: Insights from SENIORS. *European Journal of Heart Failure*, *14*(10), 1171–1178. https://doi.org/10.1093/eurjhf/hfs100

Okamoto, H., Hori, M., Matsuzaki, M., Tsutsui, H., Yamazaki, T., Nagai, R., Yoshikawa, T., Fujio, Y., Nonen, S., Azuma, J., Izumi, T., Ohashi, Y., & Kitabatake, A. (2013). Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study. *International Journal of Cardiology*, *164*(2), 238–244. https://doi.org/10.1016/j.ijcard.2012.11.051

Ozaydin, M., Yucel, H., Kocyigit, S., Adali, M. K., Aksoy, F., Kahraman, F., Uysal, B. A., Erdogan, D., Varol, E., & Dogan, A. (2016). Nebivolol versus Carvedilol or Metoprolol in Patients Presenting with Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction. *Medical Principles and Practice*, *25*(4), 316–322. https://doi.org/10.1159/000446184

Pearse, S. G., & Cowie, M. R. (2014). Heart failure: Classification and pathophysiology. *Medicine*, *42*(10), 556–561. https://doi.org/10.1016/j.mpmed.2014.07.012

Ponikowski, P., Spoletini, I., Coats, A. J. S., Piepoli, M. F., & Rosano, G. M. C. (2019). Heart rate and blood pressure monitoring in heart failure. *European Heart Journal Supplements*, *21*(Supplement_M), M13–M16. https://doi.org/10.1093/eurheartj/suz217

Ramdhani, A., Ramdhani, M. A., & Amin, A. S. (2014). Writing a Literature Review Research Paper: A step-by-step approach. *International Journal of Basic and Applied Science*, *03*(01), 10.

Rienstra, M., Damman, K., Mulder, B. A., Van Gelder, I. C., McMurray, J. J. V., & Van Veldhuisen, D. J. (2013). Beta-Blockers and Outcome in Heart Failure and Atrial Fibrillation. *JACC: Heart Failure*, *1*(1), 21–28. https://doi.org/10.1016/j.jchf.2012.09.002

Ruiz, G., Andrey, J. L., Puerto, J. L., Escobar, M. A., Romero, S. P., Aranda, R., Pedrosa, M. J., & Gomez, F. (2016). Prognosis of heart failure with preserved ejection fraction treated with β-blockers: A propensity matched study in the community. *International Journal of Cardiology*, *222*, 594–602. https://doi.org/10.1016/j.ijcard.2016.07.292

Safi, S., Korang, S. K., Nielsen, E. E., Sethi, N. J., Feinberg, J., Gluud, C., & Jakobsen, J. C. (2017). Beta-blockers for heart failure. *Cochrane Database of Systematic Reviews*. https://doi.org/10.1002/14651858.CD012897

Silverman, D. N., Plante, T. B., Infeld, M., Callas, P. W., Juraschek, S. P., Dougherty, G. B., & Meyer, M. (2019). Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial. *JAMA Network Open*, *2*(12), e1916598. https://doi.org/10.1001/jamanetworkopen.2019.16598

Toyoda, S., Haruyama, A., Inami, S., Arikawa, T., Saito, F., Watanabe, R., Sakuma, M., Abe, S., Nakajima, T., Tanaka, A., Node, K., & Inoue, T. (2020). Effects of carvedilol vs bisoprolol on inflammation and oxidative stress in patients with chronic heart failure. *Journal of Cardiology*, *75*(2), 140–147. https://doi.org/10.1016/j.jjcc.2019.07.011

Tsujimoto, T., & Kajio, H. (2018). Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction. *Scientific Reports*, *8*(1), 9556. https://doi.org/10.1038/s41598-018-27799-y

Tsutsui, H., Momomura, S., Masuyama, T., Saito, Y., Komuro, I., Murohara, T., Kinugawa, S., & on behalf of CIBIS-J Investigators. (2019). Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction ― The CIBIS-J Trial ―. *Circulation Journal*, *83*(6), 1269–1277. https://doi.org/10.1253/circj.CJ-18-1199

Turgeon, R. D., Kolber, M. R., Loewen, P., Ellis, U., & McCormack, J. P. (2019). Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis. *PLOS ONE*, *14*(2), e0212907. https://doi.org/10.1371/journal.pone.0212907

Virgadamo, S. (2015). Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. *World Journal of Cardiology*, *7*(11), 808. https://doi.org/10.4330/wjc.v7.i11.808

Xu, T., Huang, Y., Zhou, H., Bai, Y., Huang, X., Hu, Y., Xu, D., Zhang, Y., & Zhang, J. (2019). β-blockers and risk of all-cause mortality in patients with chronic heart failure and atrial fibrillation—A meta-analysis. *BMC Cardiovascular Disorders*, *19*(1), 135. https://doi.org/10.1186/s12872-019-1079-2

Yamamoto, K., Origasa, H., Hori, M., & on behalf of the J-DHF Investigators. (2013). Effects of carvedilol on heart failure with preserved ejection fraction: The Japanese Diastolic Heart Failure Study (J-DHF). *European Journal of Heart Failure*, *15*(1), 110–118. https://doi.org/10.1093/eurjhf/hfs141

Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., Johnson, M. R., Kasper, E. K., Levy, W. C., Masoudi, F. A., McBride, P. E., McMurray, J. J. V., Mitchell, J. E., Peterson, P. N., Riegel, B., … Wilkoff, B. L. (2013). 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. *Journal of the American College of Cardiology*, *62*(16), 1495–1539. https://doi.org/10.1016/j.jacc.2013.05.020

Zheng, S. L., Chan, F. T., Nabeebaccus, A. A., Shah, A. M., McDonagh, T., Okonko, D. O., & Ayis, S. (2018). Drug treatment effects on outcomes in heart failure with preserved ejection fraction: A systematic review and meta-analysis. *Heart*, *104*(5), 407–415. https://doi.org/10.1136/heartjnl-2017-311652

Ziff, O. J., Samra, M., Howard, J. P., Bromage, D. I., Ruschitzka, F., Francis, D. P., & Kotecha, D. (2020). Beta-blocker efficacy across different cardiovascular indications: An umbrella review and meta-analytic assessment. *BMC Medicine*, *18*(1), 103. https://doi.org/10.1186/s12916-020-01564-3